283. Acquired pure red cell aplasia
17 clinical trials,   36 drugs   (DrugBank: 19 drugs),   16 drug target genes,   91 drug target pathways

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04423367
(ClinicalTrials.gov)
September 13, 20205/6/2020Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line TreatmentSafety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II TrialAcquired Pure Red Cell AplasiaDrug: bortezomib/dexamethasoneInstitute of Hematology & Blood Diseases HospitalNULLRecruiting18 Years70 YearsAll17Phase 2China
2NCT04470804
(ClinicalTrials.gov)
August 1, 20209/7/2020Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCASirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective StudyPure Red Cell Aplasia, AcquiredDrug: Sirolimus;Drug: Cyclosporine ABing HanNULLNot yet recruiting18 Years70 YearsAll40Phase 4China
3NCT03966053
(ClinicalTrials.gov)
September 13, 201923/5/2019The Use of Trifluoperazine in Transfusion Dependent DBAPhase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan AnemiaDiamond Blackfan Anemia;Pure Red Cell AplasiaDrug: TrifluoperazineAdrianna VlachosNULLRecruiting18 Years65 YearsAll24Phase 1;Phase 2United States
4NCT03918265
(ClinicalTrials.gov)
May 4, 201916/4/2019Tacrolimus Treatment for Refractory Autoimmune CytopeniaTacrolimus Treatment for Refractory Autoimmune CytopeniaAutoimmune Hemolytic Anemia;Pure Red Cell Aplasia;Evans SyndromeDrug: TacrolimusPeking Union Medical College HospitalNULLRecruiting18 Years80 YearsAll80Phase 4China
5NCT03540472
(ClinicalTrials.gov)
June 10, 201814/5/2018Tacrolimus Treatment for Refractory PRCATacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective StudyPure Red Cell AplasiaDrug: tacrolimusPeking Union Medical College HospitalNULLUnknown status18 Years80 YearsAll30Phase 4China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03364764
(ClinicalTrials.gov)
January 201821/11/2017Sirolimus Treatment for Refractory PRCASirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective StudyPure Red Cell AplasiaDrug: SirolimusBing HanNULLRecruiting18 Years80 YearsAll30Phase 4China
7NCT03333486
(ClinicalTrials.gov)
December 7, 20172/11/2017Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerA Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem CellsAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Acute Leukemia in Remission;Acute Lymphoblastic Leukemia;Acute Myeloid Leukemia;Acute Myeloid Leukemia With FLT3/ITD Mutation;Acute Myeloid Leukemia With Gene Mutations;Aplastic Anemia;B-Cell Non-Hodgkin Lymphoma;CD40 Ligand Deficiency;Chronic Granulomatous Disease;Chronic Leukemia in Remission;Chronic Lymphocytic Leukemia;Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Chronic Myelomonocytic Leukemia;Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;Congenital Amegakaryocytic Thrombocytopenia;Congenital Neutropenia;Congenital Pure Red Cell Aplasia;Glanzmann Thrombasthenia;Immunodeficiency Syndrome;Myelodysplastic Syndrome;Myelofibrosis;Myeloproliferative Neoplasm;Paroxysmal Nocturnal Hemoglobinuria;Plasma Cell Myeloma;Polycythemia Vera;Recurrent Non-Hodgkin Lymphoma;Refractory Non-Hodgkin Lymphoma;Secondary Acute Myeloid Leukemia;Secondary Myelodysplastic Syndrome;Severe Aplastic Anemia;Shwachman-Diamond Syndrome;Sickle Cell Disease;T-Cell Non-Hodgkin Lymphoma;Thalassemia;Waldenstrom Macroglobulinemia;Wiskott-Aldrich SyndromeDrug: Cyclophosphamide;Drug: Fludarabine Phosphate;Other: Laboratory Biomarker Analysis;Procedure: Peripheral Blood Stem Cell Transplantation;Radiation: Total-Body IrradiationRoswell Park Cancer InstituteNational Cancer Institute (NCI)Recruiting1 Year75 YearsAll58Phase 2United States
8NCT03214354
(ClinicalTrials.gov)
July 5, 20175/7/2017Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorA Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID)Sickle Cell Disease;Stem Cell Transplant Complications;Red Blood Cell Disorder;Pure Red Cell AplasiaDrug: Alemtuzumab;Radiation: Total Body Irradiation;Drug: SirolimusUniversity of CalgaryNULLRecruiting1 Year19 YearsAll12Phase 2Canada
9NCT01362595
(ClinicalTrials.gov)
June 201320/5/2011Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan AnemiaThe Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan AnemiaDiamond Blackfan Anemia;Blackfan Diamond Syndrome;DBA;Congenital Hypoplastic Anemia;Pure Red Cell AplasiaDrug: leucineNorthwell HealthNULLActive, not recruiting2 YearsN/AAll50Phase 1;Phase 2United States
10NCT01288131
(ClinicalTrials.gov)
January 20091/2/2011Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) TreatmentRandomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and PrednisoloneAnti-r-HuEpo Associated PRCA SubjectsDrug: Cyclosporine combine with mycophenolate mofetil;Drug: Cyclophosphamide + predChulalongkorn UniversityNULLTerminated18 Years60 YearsBoth8Phase 3Thailand
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00314795
(ClinicalTrials.gov)
April 6, 200613/4/2006Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney DiseaseAn Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney DiseaseAnemia;Chronic Kidney Disease;Chronic Renal Failure;Pure Red Cell AplasiaDrug: PeginesatideTakedaNULLCompleted18 YearsN/AAll22Phase 2France;Germany;United Kingdom
12EUCTR2005-004944-30-DE
(EUCTR)
08/03/200620/12/2005A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia.An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection (Hematideā„¢) in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
INN or Proposed INN: peginesatide
Other descriptive name: Hematide, peginesatide
Product Name: AF37702 Injection
Product Code: AF37702, Hematide
INN or Proposed INN: peginesatide
Other descriptive name: Hematide, peginesatide
Takeda Development Centre Europe LtdNULLNot RecruitingFemale: yes
Male: yes
40Phase 2Germany;United Kingdom
13EUCTR2005-004944-30-GB
(EUCTR)
23/02/200609/12/2005A Phase 2 study of AF37702 Injection for anemia in patients with pure red cell aplasia.An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease - AFX01-06 Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
MedDRA version: 18.0;Level: PT;Classification code 10002965;Term: Aplasia pure red cell;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Takeda Development Centre Europe LtdNULLNot Recruiting Female: yes
Male: yes
40Phase 2Germany;United Kingdom
14NCT00229619
(ClinicalTrials.gov)
September 200529/9/2005Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaA Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaAnemia, Aplastic;Red-Cell Aplasia, Pure;Anemia, Diamond-BlackfanDrug: RituximabNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted2 YearsN/AAll11Phase 2United States
15NCT00006055
(ClinicalTrials.gov)
March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00001962
(ClinicalTrials.gov)
November 199918/1/2000A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureA Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaAplastic Anemia;Pure Red Cell Aplasia;Diamond Blackfan AnemiaDrug: DaclizumabNeal Young, M.D.NULLTerminated2 YearsN/AAll100Phase 2United States
17NCT00004143
(ClinicalTrials.gov)
September 199910/12/1999Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure SyndromesAllogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure SyndromesSickle Cell Anemia;Severe Aplastic Anemia;Paroxysmal Nocturnal Hemoglobinuria (PNH);Pure Red Cell AplasiaDrug: Campath, Chemo and/or TBI Allo SCTDavid Rizzieri, MDNULLCompleted18 YearsN/AAll2Phase 2United States